The Cooper Companies, Inc.

Its own filings show that most revenue comes from repeat purchases of contact lenses sold through eye-care professionals, distributors and retailers, with a smaller share from consumable devices and services sold into fertility clinics and women's-health providers. Separately, the recomputed financial history shows net income positive in every year on file, alongside multi-year patterns of rising revenue, positive free cash flow and receivables rising alongside revenue.

Scaling this business has meant physically expanding manufacturing: its own account cites new facility and production-line expansions and a new distribution center, rather than scaling through software or network effects. This is consistent with a broader pattern CompanyGraph sees across many companies whose output is capped by physical production rate, where growth comes from adding throughput capacity rather than from serving more customers off the same fixed base. Over recent multi-year periods this has coincided with steady, rather than volatile, growth in revenue, cash flow and book value.

Its own account of its manufacturing process names chemicals, packaging materials, components, parts and mechanical equipment as inputs, without disclosing which suppliers provide them or where they are located. The company states that its growth depends on a steady supply of production materials at reasonable cost, sufficient manufacturing capacity, and the timely approval of its products by regulators. CompanyGraph also places it downstream of another industry that feeds its inputs, though CompanyGraph does not have a name for that industry on file.

Its own account describes selling through distributors, group-purchasing organizations, practices, retail chains, hospitals and clinics, which in turn reach eye-care patients, and for its women's-health business, fertility clinics and families using donor-gamete, cryostorage and genomic services directly. Its own disclosures state that no single customer accounts for a large enough share of revenue to be separately named, which points to a downstream customer base that is broad rather than concentrated. CompanyGraph also maps it as supplying several other industries downstream.

CompanyGraph places this business within a large group of other companies that run the same kind of throughput-capped production system, so the underlying operating shape itself is common rather than rare. The company's own account claims specific strengths within that shape, a wide range of lens materials and parameters, fitting success, and its own estimate of being the most-worn contact lens brand by number of wearers, alongside broader claims of product quality, service and reliability. CompanyGraph has not independently verified these claims or assessed whether competitors can replicate them.

For its long-duration storage services, its own account discloses that stem-cell storage contracts are typically structured to run either about a year or for a period measured in decades, and the long-form contracts tie a customer to the arrangement over a very long horizon. CompanyGraph has not seen equivalent contract-length, backlog or retention disclosures for the rest of the business, including the contact lens business, so no broader switching-cost reading is made here.

CompanyGraph's starting expectation for this kind of production system, drawn from the wider industry pattern rather than measured for this company specifically, is that its scale is capped by physical manufacturing throughput. The company's own account of what limits its growth is consistent with that expectation: it names manufacturing capacity, the timely supply of production materials, and manufacturing efficiency as constraints, and it also adds regulatory approval timing and market acceptance or reimbursement as further limits, so more than physical throughput alone appears to be at work.

Its own filings list adverse political and economic conditions abroad, international conflicts, tariffs and trade barriers, and currency and interest-rate movements as the risks it names first, consistent with a workforce spread across the Americas, Europe and Asia. It also carries debt at variable rates, which ties part of its cost structure to interest-rate movements. Its own disclosures state that no single customer is large enough to be separately named, which narrows customer concentration as a specific vulnerability without addressing the others it names.

Its own filings name political, economic and international-conflict conditions, tariffs and trade barriers, and currency and interest-rate movements as the pressures it lists first among its risks, reflecting an operating footprint that spans the Americas, Europe and Asia. It specifically names exposure to tariffs on goods moving between the United States and China, and to sanctions and export-control regimes. It also operates under multiple medical-device regulators at once, including the FDA in the United States, device and diagnostic regulation in the European Union, and equivalent authorities in China and Japan, each of which can gate what it is allowed to sell and where.